Ascletis Signs an Exclusive License Agreement with Alphamab for its KN035

 Ascletis Signs an Exclusive License Agreement with Alphamab for its KN035

Ascletis Signs an Exclusive License Agreement with Alphamab for its KN035

Shots:
  • Alphamab to receive upfront, milestones and royalties on sales of KN035 (ASC22). Ascletis to get exclusive development and commercialization rights for Alphamab’s KN035 (ASC22) in Greater China
  • Alphamab will be responsible to manufacture and commercialize ASC22 (KN035) in Greater China and Ascletis to receive economics (Ex-China) from Alphamab on its regulatory approval in China
  • KN035 (ASC22) is an anti-PD-L1 mAb, targeted to treat chronic Hepatitis B and viral diseases across the US, China and Japan
Click here to read full press release/ article | Ref: PRNewswire | Image: Select Science

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post